APTBIO Announces Completion of Series C Financing Round Led by GF Xinde with Participation from Shengshi Capital

The Most Beautiful April Days on Earth: At This Time of Vibrant Spring, a Leading Enterprise in Life Science Technology Services Driven by Mass Spectrometry-Based Multi-OmicsAPTBIO Announces Completion of C-Series Financing Round Worth Hundreds of Millions of Yuan, this round of financing was led by GF Xinde, with participation from SUN ROCK CAPITAL, while HAOYUE CAPITAL continued to serve as the exclusive financial advisor for this round.This round of financing will enable APTBIO to accelerate the development of innovative products based on multi-omics application scenarios, deepen its presence in the technology services and biopharmaceutical R&D sectors, further expand into high-potential emerging industries such as consumer healthcare within the broader health sector, and speed up its global market expansion.

Founded in 2004 and headquartered in Shanghai, APTBIO—formerly the Proteomics Research and Analysis Center of the Chinese Academy of Sciences’ Shanghai Institutes for Biological Sciences—is a leading provider of life science technology services driven by mass spectrometry-based multi-omics. The company remains committed to leveraging market demand and technological innovation to continuously expand the application scenarios of mass spectrometry multi-omics. With robust R&D and commercialization capabilities, it has launched highly competitive innovative multi-omics products and solutions, maintaining a leading market share.

In recent years, multi-omics integrated analysis has become a mainstream trend, playing a pivotal role in elucidating disease mechanisms, screening novel drug targets, discovering biomarkers, and guiding personalized therapy and medication. The company possessesChina's first fully self-built multi-omics technology platform, covering five major omics platforms: genomics, proteomics, metabolomics, single-cell omics, and spatial omics.With nearly 20 years of experience in technology services and the pharmaceutical sector, the company possesses the capability to integrate and analyze large-scale clinical cohort data, providing end-to-end CRO services from drug target screening to clinical trials. Equipped with a comprehensive array of high-end instruments and facilities, the company adheres to multiple quality management systems, including ISO9001, CMA, CNAS, and D&B certifications. By leveraging high-throughput automated experimental platforms, data analysis platforms, and an intelligent laboratory management system, the company has established first-class, high-quality service capabilities, becoming the most trusted technical service provider for its clients.

Currently, corporate partners include more than 2,000 research institutes and universities, over 1,500 hospitals, and 2,500+ renowned biopharmaceutical companies, among others.Accumulated service projects exceed 30,000; over 2,000 SCI articles have been published in collaboration with project partners, with a cumulative impact factor exceeding 15,000.Through technological collaboration and independent innovation, the company has established four major technical platforms: a large-cohort multi-omics research technology platform, an early-stage research and preclinical CMC analysis platform for biopharmaceuticals, a registration and regulatory approval platform for biologics and combination products, and an AI big data algorithm platform. It has laid out three core business segments—technology services, biopharmaceuticals, and CRO services for consumer healthcare within the broader health sector—thereby constructing a commercial landscape in life sciences and general health that integrates AI big data with mass spectrometry-based multi-omics technologies.

With the support of this round of financing, the Company will continue to uphold its corporate values of “innovation as the foundation, integrity as the priority, and pragmatism as the key,” accelerate the expansion and upgrading of its technology platforms, further deploy multi-omics technologies in emerging scenarios such as consumer healthcare within the broader health sector, and speed up the expansion of global marketing channels and the recruitment of high-end talent. The Company strives to become a global leader in multi-omics technologies and life science technology services, promote the development of innovative multi-omics technologies, accelerate the translational application of multi-omics achievements in fields including clinical diagnostics, drug R&D, personalized medication, aging research, and food safety, and empower the sustained, high-quality development of China’s life science and general health industries.

Ms. Chen Wei, Founder of APTBIOstated, expressing gratitude to all investment institutions for their trust in APTBIO. The capital injection in this round fully validates APTBIO’s development capabilities and future potential in the field of mass spectrometry-based multi-omics. We will further explore innovative applications and development of mass spectrometry-based multi-omics across broader health industries, accelerate our global market expansion and the iterative advancement of innovative biopharmaceutical businesses, and contribute value to the global human health industry.

Dr. Li Chen, GF XindeAPTBIO has focused on the high-potential market for mass spectrometry-based multi-omics. After years of development, it has become a leading life science technology service company in China, with its services covering multiple rapidly growing application areas. Built on solid technology and excellent service, the company is widely favored and trusted by clients across various sectors. Meanwhile, its management team possesses forward-looking strategic vision and outstanding, efficient execution capabilities, demonstrating the courage to continuously explore new business domains. We are delighted to partner with the company and will, through proactive value-added services, help APTBIO become a world-class life science technology service enterprise.

SUN ROCK CAPITALAPTBIO, which traces its heritage to the Proteomics Research and Analysis Center of the Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, is a premier enterprise consistently pioneering innovative concepts in testing services. At the forefront of the proteomics analysis service sector, the company has established a Corporate Innovation Research Institute by leveraging technical collaborations with leading domestic and international research institutions and the innovative capabilities of its in-house R&D team. It has built a large-cohort multi-omics research technology platform, an early-stage research and preclinical CMC (Chemistry, Manufacturing, and Controls) analysis platform for biopharmaceuticals, and a regulatory submission platform for biologics and combination products. As a rare industry leader, APTBIO has strategically positioned itself across scientific research services, biopharmaceutical CRO services, and consumer healthcare CRO services. SUN ROCK CAPITAL is optimistic about APTBIO’s long-term development prospects and looks forward to joining hands with the company through this investment to jointly participate in and promote the growth of the biopharmaceutical industry in the Yangtze River Delta region.

Mr. Ding Yameng, Founding Managing Partner and Chief Operating Officer of HAOYUE CAPITALHAOYUE CAPITAL expressed that it is a great honor to once again assist APTBIO in completing its latest round of financing. In recent years, mass spectrometry-based multi-omics has witnessed rapid development in China, with continuously expanding application scenarios and broad market potential. We believe this financing will further consolidate APTBIO’s leading position in China’s mass spectrometry multi-omics industry and lay a solid foundation for the company’s future high-speed growth. Throughout our collaboration with APTBIO, the HAOYUE CAPITAL team has been deeply impressed by the steady and pragmatic working style, as well as the enterprising spirit of innovation, demonstrated by the company’s team led by Ms. Chen Wei. We are confident that APTBIO will become a globally leading life science technology service provider, contributing to the sustained development of China’s life sciences and biopharmaceutical industries.

GF Xinde Investment Management Co., Ltd.Established in December 2008, GF Xinde Investment Management Co., Ltd. is a wholly-owned private equity fund subsidiary of GF Securities Co., Ltd. (Stock Code: 000776) and ranks among the leading private equity subsidiaries of securities firms in China. Leveraging its superior fund management capabilities, excellent investment research expertise, comprehensive project management skills, and rigorous, pragmatic compliance and risk control measures, GF Xinde has become a preferred capital allocation choice for numerous high-quality investors. Upholding the values of vision, integrity, and collaboration, the company identifies high-quality projects based on in-depth industry research. Furthermore, by relying on the comprehensive advantages of the GF Securities Financial Group and its own strategic management capabilities, GF Xinde provides all-around value-added services to portfolio companies, enhancing their investment value and generating substantial returns for investors, thereby achieving a win-win outcome for the company, investors, and portfolio companies. GF Xinde has consistently ranked among the top three in Zero2IPO’s rankings of private equity managers affiliated with securities firms. Currently, the funds raised and managed by the company cover multiple sectors, including healthcare, consumption upgrades, industrial innovation and upgrading, and TMT, spanning various investment categories such as private equity (PE), venture capital (VC), and mergers and acquisitions (M&A).

As a professional investment institution under the Shanghai Guosheng Group, SUN ROCK CAPITAL has long focused on industrial investment opportunities in strategic emerging sectors such as “New Intelligent Manufacturing, New Energy, New Healthcare, and Next-Generation Information Technology.” Leveraging its outstanding performance and forward-looking strategic layout in investment tracks including biopharmaceuticals, integrated circuits, artificial intelligence, new energy, and next-generation information technology, SUN ROCK CAPITAL has received numerous awards, including “Top 100 Chinese Private Equity Investment Institutions of 2023” by Rongzhong, “China Industrial Investment Ranking 2021–2022,” and “China New Economy Enterprise Ranking 2021–2022.”